+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiac Biomarkers Market Size, Share & Trends Analysis Report by Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), Application, End-use, and Region with Growth Forecasts, 2025-2030- Product Image
Cardiac Biomarkers Market Size, Share & Trends Analysis Report by Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), Application, End-use, and Region with Growth Forecasts, 2025-2030- Product Image
New

Cardiac Biomarkers Market Size, Share & Trends Analysis Report by Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), Application, End-use, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 5899489
Description Jump to:
The Cardiac Biomarkers Market was valued at USD 23.24 billion in 2024, and is projected to reach USD 51.19 billion by 2030, rising at a CAGR of 14.10%. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the report by Cleveland Clinic, more than 18 million adults in the U.S. were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S., and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The rising adoption of biomarkers in risk stratification and diagnosis of acute coronary syndrome is increasing the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making the use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin.

Cardiac Biomarkers Market Report Highlights

  • In terms of type, the troponin segment held the largest revenue share of over 35.5% in 2024 owing to its high usage in cardiovascular disease diagnosis
  • Based on application, the acute coronary syndrome segment is expected to grow at the fastest CAGR during 2025-2030
  • In terms of end use, laboratory testing segment dominated the market in 2024
  • North America dominated the global market in 2024 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
  • Key players operating in the cardiac biomarkers market include Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Danaher, BIOMÉRIEUX, Bio-Rad Laboratories Inc, Randox Laboratories Ltd, Creative Diagnostics, Life Diagnostics
  • The rise in the availability of novel assays is one of the major drivers anticipated to boost market growth in the upcoming years. For instance, in October 2023, Mindray launched two highly sensitive cardiac biomarkers assays, hs-cTnI Assay, and NT-proBNP Assay, to diversify its portfolio in cardio biomarkers to provide enhanced cardiovascular disease care.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Application
2.2.3. End Use
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Cardiac Biomarkers Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market outlook
3.1.2. Related/ancillary Market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Cardiac Biomarkers Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Cardiac Biomarkers Market : Pipeline Analysis
Chapter 4. Cardiac Biomarkers Market : Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Cardiac Biomarkers Market: Type Movement Analysis
4.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Troponin
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. CK-MB
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Myoglobin
4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Irreversible Electroporation Ablation
4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. BNP AND NT-PROBNP
4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Cardiac Biomarkers Market : Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. Cardiac Biomarkers Market: Application Movement Analysis
5.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Acute Coronary Syndrome
5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Myocardial Infarction
5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Congestive Heart Failure
5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Cardiac Biomarkers Market: End Use Estimates & Trend Analysis
6.1. End Use Segment Dashboard
6.2. Cardiac Biomarkers Market: End Use Movement Analysis
6.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Laboratory Testing
6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.5. Point of Care Testing
6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Cardiac Biomarkers Market : Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous bioprocessing Market by Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. U.S. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Canada Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Mexico
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. Mexico Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. UK Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Germany Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. France Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Italy Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Spain Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. Norway
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Norway Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework/ reimbursement structure
7.5.7.3. Competitive scenario
7.5.7.4. Sweden Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework/ reimbursement structure
7.5.8.3. Competitive scenario
7.5.8.4. Denmark Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Japan Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. China Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. India Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Australia Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. South Korea Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Thailand Market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Brazil Market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Argentina Market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. South Africa Market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Saudi Arabia Market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. UAE Market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.4. Kuwait
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework/ reimbursement structure
7.8.4.3. Competitive scenario
7.8.4.4. Kuwait Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
8.4.1. Abbott
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Quidel Corporatio
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Siemens Healthcare Gmbh
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. F. Hoffmann-La Roche Ltd.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Danaher
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. BIOMÉRIEUX
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Bio-Rad Laboratories, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Randox Laboratories Ltd.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Creative Diagnostics
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Life Diagnostics
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 3 North America cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 4 North America cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 5 North America cardiac biomarkers market, by region, 2018-2030 (USD Million)
Table 6 U.S cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 7 U.S cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 8 U.S cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 9 Canada cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 10 Canada cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 11 Canada cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 12 Europe cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 13 Europe cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 14 Europe cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 15 Europe cardiac biomarkers market, by region, 2018-2030 (USD Million)
Table 16 Germany cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 17 Germany cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 18 Germany cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 19 UK cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 20 UK cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 21 UK cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 22 France cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 23 France cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 24 France cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 25 Italy cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 26 Italy cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 27 Italy cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 28 Spain cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 29 Spain cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 30 Spain cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 31 Denmark cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 32 Denmark cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 33 Denmark cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 34 Sweden cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 35 Sweden cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 36 Sweden cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 37 Norway cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 38 Norway cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 39 Norway cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 40 Asia Pacific cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 41 Asia Pacific cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 42 Asia Pacific cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 43 Asia Pacific cardiac biomarkers market, by region, 2018-2030 (USD Million)
Table 44 Japan cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 45 Japan cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 46 Japan cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 47 China cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 48 China cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 49 China cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 50 India cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 51 India cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 52 India cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 53 Australia cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 54 Australia cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 55 Australia cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 56 Thailand cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 57 Thailand cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 58 Thailand cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 59 South Korea cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 60 South Korea cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 61 South Korea cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 62 Latin America cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 63 Latin America cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 64 Latin America cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 65 Latin America cardiac biomarkers market, by region, 2018-2030 (USD Million)
Table 66 Brazil cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 67 Brazil cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 68 Brazil cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 69 Mexico cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 70 Mexico cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 71 Mexico cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 72 Argentina cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 73 Argentina cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 74 Argentina cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 75 Middle East and Africa cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 76 Middle East and Africa cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 77 Middle East and Africa cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 78 Middle East and Africa cardiac biomarkers market, by region, 2018-2030 (USD Million)
Table 79 South Africa cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 80 South Africa cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 81 South Africa cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 82 Saudi Arabia cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 83 Saudi Arabia cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 84 Saudi Arabia cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 85 UAE cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 86 UAE cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 87 UAE cardiac biomarkers market, by end use, 2018-2030 (USD Million)
Table 88 Kuwait cardiac biomarkers market, by type, 2018-2030 (USD Million)
Table 89 Kuwait cardiac biomarkers market, by application, 2018-2030 (USD Million)
Table 90 Kuwait cardiac biomarkers market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 QFD modeling for market share assessment
Figure 6 Market formulation & validation
Figure 7 Cardiac biomarkers: Market outlook
Figure 8 Cardiac biomarkers: Competitive insights
Figure 9 Parent market outlook
Figure 10 Related/ancillary market outlook
Figure 11 Penetration and growth prospect mapping
Figure 12 Cardiac biomarkers market driver impact
Figure 13 Cardiac biomarkers market restraint impact
Figure 14 Cardiac biomarkers market strategic initiatives analysis
Figure 15 Cardiac biomarkers market: Type movement analysis
Figure 16 Cardiac biomarkers market: Type outlook and key takeaways
Figure 17 Troponin market estimates and forecasts, 2018-2030 (USD Million)
Figure 18 CK-MB market estimates and forecasts, 2018-2030 (USD Million)
Figure 19 Myoglobin market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 BNP and NT-proBNP market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 Cardiac biomarkers market: Application movement analysis
Figure 23 Cardiac biomarkers market: Application outlook and key takeaways
Figure 24 Acute coronary syndrome market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 Myocardial infarction market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Congestive heart failure market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Other applications market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 Cardiac biomarkers market: End use movement analysis
Figure 29 Cardiac biomarkers market: End use outlook and key takeaways
Figure 30 Laboratory testing market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Point of care testing market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Pain management market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Cancer therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Vaccine delivery market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Other end use market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Global cardiac biomarkers market: Regional movement analysis
Figure 37 Global cardiac biomarkers market: Regional outlook and key takeaways
Figure 38 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 U.S market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 59 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 62 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

The major companies featured in this Cardiac Biomarkers market report include:
  • Quidel Corporation
  • Siemens Healthcare GmbH
  • F. Hoffmann-La Roche Ltd.
  • Danaher
  • BIOMÉRIEUX
  • Bio-Rad Laboratories, Inc.
  • Randox Laboratories Ltd.
  • Creative Diagnostics
  • Life Diagnosti

Table Information

Report AttributeDetails
No. of Pages100
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 23.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 51.19 Billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast to 2030 - Product Image

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Cardiac Biomarker Diagnostic Kits Market by Biomarker Type, Indication, Testing Type, Purchasing Mode, Application, End User - Global Forecast to 2030 - Product Image

Cardiac Biomarker Diagnostic Kits Market by Biomarker Type, Indication, Testing Type, Purchasing Mode, Application, End User - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Cardiac Biomarker Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Cardiac Biomarker Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 92 Pages
  • Global
From
Cardiac Biomarkers Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Cardiac Biomarkers Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 153 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.